Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Mar, 2016 | Pages:
40 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Review, H1 2016', provides an overview of the Fibrinogen Deficiency (Factor I Deficiency) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Fibrinogen Deficiency (Factor I Deficiency), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fibrinogen Deficiency (Factor I Deficiency) and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Fibrinogen Deficiency (Factor I Deficiency) - The report reviews pipeline therapeutics for Fibrinogen Deficiency (Factor I Deficiency) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Fibrinogen Deficiency (Factor I Deficiency) therapeutics and enlists all their major and minor projects - The report assesses Fibrinogen Deficiency (Factor I Deficiency) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Fibrinogen Deficiency (Factor I Deficiency) Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Fibrinogen Deficiency (Factor I Deficiency) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Fibrinogen Deficiency (Factor I Deficiency) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Fibrinogen Deficiency (Factor I Deficiency) Overview 6 Therapeutics Development 7 Pipeline Products for Fibrinogen Deficiency (Factor I Deficiency) - Overview 7 Fibrinogen Deficiency (Factor I Deficiency) - Therapeutics under Development by Companies 8 Fibrinogen Deficiency (Factor I Deficiency) - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Early Stage Products 11 Fibrinogen Deficiency (Factor I Deficiency) - Products under Development by Companies 12 Fibrinogen Deficiency (Factor I Deficiency) - Companies Involved in Therapeutics Development 13 Biotest AG 13 China Biologic Products, Inc. 14 Grifols, S.A. 15 LFB S.A. 16 Octapharma AG 17 Fibrinogen Deficiency (Factor I Deficiency) - Therapeutics Assessment 18 Assessment by Monotherapy Products 18 Assessment by Target 19 Assessment by Mechanism of Action 20 Assessment by Route of Administration 21 Assessment by Molecule Type 23 Drug Profiles 24 fibrinogen (human) - Drug Profile 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 fibrinogen concentrate (human) - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 fibrinogen concentrate (human) - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 fibrinogen concentrate (human) - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 fibrinogen concentrate (human) - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Fibrinogen Deficiency (Factor I Deficiency) - Recent Pipeline Updates 30 Fibrinogen Deficiency (Factor I Deficiency) - Dormant Projects 31 Fibrinogen Deficiency (Factor I Deficiency) - Discontinued Products 32 Fibrinogen Deficiency (Factor I Deficiency) - Product Development Milestones 33 Featured News & Press Releases 33 Dec 19, 2012: CSL Behring's Fibrinogen Concentrate Given As First-Line Therapy Safely Reduces Need For Transfusion After Aortic Surgery In Phase II Study 33 Mar 23, 2012: China Biologic Receives SFDA Approval To Begin Clinical Trials For Human Fibrinogen 34 Mar 11, 2009: CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP 34 Mar 11, 2009: CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP 35 Jan 16, 2009: CSL Behring Receives FDA Approval of RiaSTAP, First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency 36 Jan 16, 2009: CSL Behring Receives FDA Approval of RiaSTAP, First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency 36 Jan 16, 2009: CSL Behring Receives FDA Approval of RiaSTAP, First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency 37 Jul 21, 2008: CSL Behring Submits BLA Requesting Approval of Human Fibrinogen Concentrate for the Treatment of Congenital Bleeding 38 Jul 21, 2008: CSL Behring Submits BLA Requesting Approval of Human Fibrinogen Concentrate for the Treatment of Congenital Bleeding 38 Appendix 39 Methodology 39 Coverage 39 Secondary Research 39 Primary Research 39 Expert Panel Validation 39 Contact Us 39 Disclaimer 40
List of Tables
Number of Products under Development for Fibrinogen Deficiency (Factor I Deficiency), H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Late Stage Development, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 10 Comparative Analysis by Early Stage Development, H1 2016 11 Products under Development by Companies, H1 2016 12 Fibrinogen Deficiency (Factor I Deficiency) - Pipeline by Biotest AG, H1 2016 13 Fibrinogen Deficiency (Factor I Deficiency) - Pipeline by China Biologic Products, Inc., H1 2016 14 Fibrinogen Deficiency (Factor I Deficiency) - Pipeline by Grifols, S.A., H1 2016 15 Fibrinogen Deficiency (Factor I Deficiency) - Pipeline by LFB S.A., H1 2016 16 Fibrinogen Deficiency (Factor I Deficiency) - Pipeline by Octapharma AG, H1 2016 17 Assessment by Monotherapy Products, H1 2016 18 Number of Products by Stage and Target, H1 2016 19 Number of Products by Stage and Mechanism of Action, H1 2016 20 Number of Products by Stage and Route of Administration, H1 2016 22 Number of Products by Stage and Molecule Type, H1 2016 23 Fibrinogen Deficiency (Factor I Deficiency) Therapeutics - Recent Pipeline Updates, H1 2016 30 Fibrinogen Deficiency (Factor I Deficiency) - Dormant Projects, H1 2016 31 Fibrinogen Deficiency (Factor I Deficiency) - Discontinued Products, H1 2016 32
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
